Tresiba Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tresiba market research report is one of a series of new reports that provides tresiba market statistics, including the tresiba industry's global market size, regional shares, competitors with a tresiba market share, detailed tresiba market segments, market trends and opportunities, and any further data you may need to thrive in the tresiba industry. This tresiba market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing prevalence of diabetes globally, rising adoption of long-acting insulin analogs, supportive government reimbursement policies, growing awareness of personalized diabetes treatment plans, expansion of healthcare infrastructure, and increasing research and development. Major trends in the forecast period include adoption of personalized dosing algorithms, advancements in insulin delivery devices, integration with continuous glucose monitoring (CGM) systems, development of biosimilar insulin options, and innovations in ultra-long-acting insulin formulations.

The increasing prevalence of diabetes is anticipated to drive the growth of the Tresiba market in the coming years. Diabetes, a chronic condition characterized by the body’s inability to regulate blood sugar levels effectively, has seen rising cases due to factors such as sedentary lifestyles, unhealthy diets, obesity, aging populations, and genetic predisposition. Tresiba offers significant benefits for diabetes management by providing improved glycemic control, reducing the risk of hypoglycemia, and offering flexible dosing options that promote better adherence to treatment. For example, in June 2023, the Institute for Health Metrics and Evaluation reported that more than half a billion people globally were living with diabetes, a number expected to exceed 1.3 billion by 2050. This growing prevalence of diabetes is fueling demand for Tresiba.

The increasing rates of obesity are another factor contributing to the growth of the Tresiba market. Obesity, defined by excessive body fat and typically assessed using body mass index (BMI), is linked to numerous health complications, including diabetes. The rise in obesity rates is attributed to changes in dietary habits, increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make unhealthy food options more accessible. Tresiba is beneficial for obese patients by offering long-acting insulin that enhances glycemic control, lowers the risk of hypoglycemia, and supports weight management through its flexible dosing options. For instance, in 2024, the UK’s Office for Health Improvement and Disparities reported that between 2022 and 2023, approximately 64% of adults in England were classified as overweight or obese, up from 63.8% in the previous year. This increase in obesity rates is driving the demand for effective insulin therapies such as Tresiba.

An emerging trend in the Tresiba market is the development of unbranded biologics, which provide affordable alternatives to branded medications, increasing access to insulin therapy while maintaining safety and efficacy. Unbranded biologics are biological medicines identical to their branded counterparts in molecular composition and performance but marketed without a brand name. For example, in September 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched an FDA-approved unbranded biologic version of Tresiba (insulin degludec), a long-acting basal insulin designed to manage high blood sugar in patients aged one and older with diabetes. This unbranded version aims to improve affordability, especially for uninsured and underinsured patients, making insulin therapies more accessible to a broader population.

The key company operating in the tresiba market is Novo Nordisk A/S.

North America was the largest region in the tresiba market in 2024. The regions covered in tresiba report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tresiba market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tresiba (insulin degludec) is a long-acting insulin designed to manage diabetes mellitus in both adults and children. It works by maintaining stable blood sugar levels in individuals with type 1 or type 2 diabetes through a sustained release of insulin over an extended period.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for tresiba are type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune disorder in which the immune system attacks and destroys the insulin-producing beta cells in the pancreas, resulting in insufficient insulin production and elevated blood glucose levels. Tresiba is distributed through various channels, including hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies. Its end users include adults, geriatric patients, and pediatric patients.

The tresiba market consists of sales of tresiba U-100, tresiba U-200, and pre-filled flextouch pen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.